<DOC>
	<DOCNO>NCT00271310</DOCNO>
	<brief_summary>The effect long term inhalation hypertonic saline subject cystic fibrosis lung function , incidence respiratory tract infection , quality life , quantitative microbiology sputum cytokine profile . The hypothesis regular inhalation nebulised hypertonic saline beneficial effect lung function clinical outcome adverse effect infection inflammation adult child cystic fibrosis .</brief_summary>
	<brief_title>The Effects Long Term Inhalation Hypertonic Saline Subjects With Cystic Fibrosis</brief_title>
	<detailed_description>The study intervention nebulised hypertonic ( 7 % ) saline ( Active ) nebulised normal ( 0.9 % ) saline ( Control ) twice per day 336 day . At screen visit , subject complete quality life questionnaire , question regard medical history , undergo physical examination spirometry , request provide sputum sample . The subject supervise take first dose ensure correct procedure use adverse effect . The subject commences take trial solution home , week completes diary card monitor factor respiratory tract infection medication use . Subsequent visit schedule Days 28 , 84 , 168 , 252 , 334 , 336 , investigation perform screening visit .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Confirmed diagnosis CF ( sweat tests/genotype ) The subject , legal guardian child 18 year old , must provide write informed consent . The subject must stable clinical condition time period 14 day prior recruitment study . Age &gt; 6 year old FEV1 &gt; 40 % predict height , age gender Proven anticipate compliance therapy study protocol Regular attendee Cystic Fibrosis Clinic ( &gt; 2 visit per year ) Able reproducibly perform lung function test ( spirometry ) Relatively stable nutritional status ( &lt; 2 kg weight loss last 6 month &lt; 5 kg weight loss last year ) Known “ normal ” ( CF subject ) laboratory test haematology , biochemistry , immunology , coagulation , etc . Requiring home oxygen ( pO2 &lt; 55mmHg pCO2 &gt; 50mmHg ) assist ventilation . Considered “ terminally ill ” list transplantation ( either lung liver ) . Subjects list transplant enrol trial eligible continue trial . Subjects colonise Burkholderia cepacia . However , subject becomes colonise B. cepacia trial , continue trial . Subjects consider B. cepacia positive even single lifetime isolate . In subject , spirometry measure dedicated spirometer . Cigarette smoker . Exposure investigational drug within past 30 day . Major haemoptysis ( &gt; 60 mL single episode ) within last twelve month . Concurrent illnesses eg . cor pulmonale , clinically significant liver disease ( portal hypertension , varix ) . Known allergy quinine sulphate , Glucose 6phosphate dehydrogenase deficiency . Immune thrombocytopaenic purpura . Pregnant lactating female . At risk female unwilling use appropriate contraception prevent pregnancy duration enrolment study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
</DOC>